YARDLEY, Pa.--(BUSINESS WIRE)--OptiNose today announced positive results from its first phase III controlled clinical trial, NAVIGATE II, evaluating the safety and efficacy of OPN-375, an investigational treatment for nasal polyps, a type of Chronic Nasal Inflammatory Disease (CNID), and the associated chronic symptoms. OPN-375 demonstrated statistically significant effects on both co-primary endpoints: reduction of patient-rated nasal congestion/obstruction symptoms (P<0.001) and endoscopically measured reduction in total polyp grade (P<0.001). Statistically significant benefits were also observed on a wide range of secondary endpoints. The incidence of adverse events with OPN-375 was consistent with the favorable results observed in previous trials.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
